Cyclops™ is an easy-to-use, pre-filled, disposable DPI that is developed for inhalation powders and can be produced in a cost-effective way because of its simple yet sophisticated proprietary design.
Upon inhalation it uses the patient’s breath to disperse the dry powder formulation into small particles appropriately sized for deep lung deposition. Cyclops™ has several advantages compared to standard-of-care DPIs across key therapeutic areas. These attributes enable the hygienic and effective use on a worldwide scale. One product, Colistin Cyclops™, is already marketed and reimbursed under a named patient regimen for the treatment of cystic fibrosis patients.
HIGHLY PREFERRED BY PATIENTS
Tuesday September 26 was an exciting day for the PureIMS team. Not
Following a successful funding round in April of this year
PureIMS secures new investment round to develop lead inhalation product and facilitate partnering activities
PureIMS today announced it has secured a new investment round.
Roden — February 10, 2023 — PureIMS, a clinical stage pharmaceutical